AstraZeneca PLC Ordinary Shares (AZN)

Total Costs & Expenses

$47.40B

TTM · Period ending: · USD

AZN logo

AZN Total Costs & Expenses

Latest reported$47.40B
AZN TTM Total Costs & Expenses ($6.57B → $47.40B)
High-resolution chart · PNG

AZN total costs & expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

AstraZeneca PLC Ordinary Shares Total Costs & Expenses — Trailing twelve months (TTM) (USD)
Period endingTotal Costs & Expenses (USD)
47,395,000,000
46,124,000,000
44,996,000,000
45,326,000,000
45,177,000,000
44,420,000,000
44,070,000,000
42,005,000,000
40,084,000,000
38,852,000,000
37,618,000,000
36,941,000,000
37,140,000,000
38,412,000,000
40,594,000,000
42,784,000,000
44,587,000,000
41,448,000,000
36,361,000,000
29,981,000,000
23,848,000,000
21,746,000,000
21,455,000,000
21,619,000,000
21,861,000,000
22,200,000,000
21,460,000,000
20,713,000,000
19,553,000,000
18,615,000,000
18,703,000,000
18,454,000,000
19,048,000,000
18,782,000,000
18,788,000,000
16,749,000,000
16,337,000,000
17,511,000,000
18,100,000,000
20,359,000,000
20,463,000,000
20,547,000,000
20,594,000,000
22,315,000,000
23,608,000,000
23,877,000,000
24,377,000,000
24,780,000,000
23,256,000,000
22,635,000,000
21,999,000,000
19,882,000,000
19,864,000,000
19,624,000,000
19,825,000,000
20,996,000,000
20,421,000,000
21,094,000,000
20,796,000,000
20,513,000,000
22,054,000,000
21,733,000,000
21,775,000,000
22,189,000,000
21,693,000,000
21,656,000,000
21,261,000,000
20,942,000,000
21,199,000,000
21,575,000,000
22,457,000,000
22,397,000,000
22,272,000,000
22,089,000,000
21,465,000,000
20,375,000,000
19,657,000,000
18,851,000,000
18,259,000,000
17,758,000,000
17,442,000,000
17,362,000,000
17,448,000,000
21,558,000,000
21,557,000,000
21,379,000,000
21,111,000,000
16,377,000,000
15,966,466,544
15,291,292,452
14,737,999,999
14,697,690,673
14,385,807,997
14,072,982,089
13,653,274,542
18,463,790,330
18,028,206,462
17,939,206,462
17,841,611,920
14,643,271,428
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.